Taylor Goodstein

Also affiliated with Emory University Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma”.

Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma

Current Opinion in Oncology(2023)10.1097/cco.0000000000000939

N/A

0DataRank · unranked

6 citations

Yuanquan Yang, Karie Runcie, Ramaprasad Srinivasan, Eric A. Singer, Taylor Goodstein

Biomarkers in advanced renal cell carcinoma: current practice and future directions

Current Opinion in Oncology(2025)10.1097/cco.0000000000001138

N/A

0DataRank · unranked

9 citations

Taylor Goodstein, Gabriela Bravo, Ramaprasad Srinivasan, Eric A. Singer, Vivian Wong